# Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians

> **NCT06519981** · EARLY_PHASE1 · COMPLETED · sponsor: **Atridia Pty Ltd.** · enrollment: 20 (actual)

## Conditions studied

- MRI

## Interventions

- **DRUG:** HRS-9231or matching placebo

## Key facts

- **NCT ID:** NCT06519981
- **Lead sponsor:** Atridia Pty Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-21
- **Primary completion:** 2024-09-29
- **Final completion:** 2024-11-27
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06519981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06519981, "Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06519981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*